First Trust Nasdaq Pharmaceuticals ETF
FTXH
3 hedge funds and large institutions have $931K invested in First Trust Nasdaq Pharmaceuticals ETF in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50.81% more ownership
Funds ownership: 0% → 50.81% (+51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$929K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$20.8K |
| 3 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
+$4.41K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $907K | +$929K | +49,468 | New |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $20K | +$20.8K | +1,108 | New |
|
|
MFS
3
MSI Financial Services
Springfield,
Massachusetts
| $4K | +$4.41K | +235 | New |
|
FTXH Hedge Fund Activity: Q4 2016 in Review
3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2016, worth a combined $931K.
Buyers outnumbered sellers: 3 funds opened new FTXH positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $929K.
- 3 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $931K of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2016.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2016 and 0 closed out, a net change of +3 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2016 was Virtu KCG Holdings, an estimated $929K added.
Based on aggregated 13F filings for Q4 2016.